Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search

		Submit


Tuberculosis (TB)


Facebook
        Twitter
        LinkedIn
        Syndicate





Reported Tuberculosis in the United States, 2017										Related Pages
										Return to Main Menu
**Appendix B**
**Recommendations for Reporting and Counting Tuberculosis Cases**
**(Revised May 13, 2009)**
Since publication of the “Recommendations for Counting Reported Tuberculosis Cases”1in July 1997, substantial changes have occurred, and questions have been raised within the field of tuberculosis (TB) surveillance. This appendix updates and supersedes previous versions.
A distinction should be made between ***reporting***TB cases to a health department and ***counting***TB cases for determining disease incidence. Throughout each year, TB cases and suspected cases are reported to public health authorities by such sources as clinics, hospitals, laboratories, and health care providers. From these reports, the state or local TB control officer must determine which cases meet the surveillance definition for TB disease and whether the case is countable. These countable TB cases are then reported to the Centers for Disease Control and Prevention (CDC).
Beginning in 2009, state and local TB control officers may also report to CDC those TB cases that are verified but not countable for morbidity statistics, as a measure of programmatic and case management burden. The noncountable report can include persons with TB disease recurring within a consecutive 12-month period after the patient completed TB therapy.
I. **Reporting TB Cases**
CDC recommends that health care providers and laboratories be re­quired to report all TB cases or suspected cases to state and local health departments on the basis of “Tuberculosis Case Definition for Public Health Surveillance” (Appendix A). This notification is essential for TB programs to:
ensure case supervision
ensure completion of recommended therapy
ensure completion of contact investigations
evaluate program effectiveness
assess trends and characteristics of TB morbidityII. **TB Surveillance**
For purposes of surveillance, a case of TB is defined on the basis of labo­ratory or clinical evidence of active disease caused by *M. tuberculosis* complex.*
*****  Because the majority of laboratories use tests that do not routinely distinguish *Mycobacterium tuberculosis* from closely related species, these laboratories report culture results as being positive or negative for “*Mycobacterium tuberculosis* complex.” Although in almost all cases of human disease, isolates in the *M. tuberculosis* complex are, in fact, *M. tuberculosis*, other species are possible. Other species in the *M. tuberculosis* complex include *M. bovis*, *M. africanum*, *M. microti*, *M. canettii*, *M. caprae*, *M. pinnipedii*, and *M. mungi*; the inclusion of these species in *M. tuberculosis* complex should not affect public health laboratories or programs because only a few laboratories identify to the species level. These seven species are approximately identical in DNA homology studies. In terms of their ability to cause clinical disease or be transmissible from person to person, *M. bovis*, *M. africanum*, *M. microti*, *M. canettii*, *M. pinnipedii*, and *M. mungi* behave like *M. tuberculosis*; therefore, disease caused by any of the organisms should be reported as TB, using the Report of Verified Case of TB (RVCT). The only exception is the bacillus Calmette-Guérin (BCG) strain of *M. bovis*, which can be isolated from persons who have received the vaccine for protection against TB or as cancer immunotherapy; disease caused by the BCG strain of *M. bovis* should not be reported as TB.
***A.* *Laboratory Case Definition***
*Isolation of M. tuberculosis complex from a clinical specimen*. The use of rapid identifi­cation techniques for *M. tuberculosis*performed on a culture from a clinical specimen (e.g., DNA probes or high-pressure liquid chromatography) is acceptable under this criterion.
***or***
*Demonstration of M. tuberculosis* *from a clinical specimen by nucleic acid amplifica­tion test.*Nucleic acid amplification (NAA) tests must be accompanied by cultures of my­cobacterial species. However, for surveillance purposes, CDC will accept results obtained from NAA tests approved by the Food and Drug Administration (FDA) and used accord­ing to the approved product labeling on the package insert, or a test produced and validat­ed in accordance with applicable FDA and Clinical Laboratory Improvement Amendments regulations.
***or***
*Demonstration of acid-fast bacilli (AFB) in a clinical specimen when a culture has not been or cannot be obtained or is falsely negative or contaminated.*Historically, this crite­rion has been most commonly used in diagnosing TB in the postmortem setting.
***B.* *Clinical Case Definition***
In the absence of laboratory confirmation of *M. tuberculosis*complex after a diagnostic process has been completed, persons must have ***all***of the following criteria for a clinical TB diagnosis:
Evidence of TB infection based on a positive tuberculin skin test result or positive inter­feron gamma release assay for *M. tuberculosis*, and current treatment with two or more anti-TB medications.
***and***
One of the following:
Signs and symptoms compatible with current TB disease (e.g., an abnormal chest radiograph or abnormal chest computerized tomography scan or other chest imag­ing study,***or***
Clinical evidence of current disease (e.g., fever, night sweats, cough, weight loss, hemoptysis).**NOTE:**The software for TB surveillance developed by CDC includes a calculated variable called “VERCRIT,” for which one of the values is Provider Diagnosis. Provider Diagnosis is se­lected when the user chooses to override a Suspect default value in the case verification screen as Verified by Provider Diagnosis. Thus, Provider Diagnosis is not a component of the case definition for TB in the “TB Case Definition for Public Health Surveillance” (Ap­pendix A). CDC’s national morbidity reports have traditionally included all TB cases that are considered verified by the reporting areas, without a requirement that cases meet the published case definition.
**III.****Counting TB Cases**
Cases that meet the CDC surveillance case definition for verified TB are counted by 52 reporting areas with count authority (50 states, the District of Columbia [DC], and New York City) to determine annual incidence for the United States. The remain­ing 8 reporting areas (American Samoa, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, Puerto Rico, Republic of Palau, and U.S. Virgin Islands) report cases to CDC but are not included in the annual incidence for the United States. The laboratory and clinical case definitions are the two diagnostic categories used in the CDC “Tuberculosis Case Definition for Public Health Surveillance” (Appendix A).
The majority of verified TB cases are accepted for counting on the basis of laboratory confirmation of *M. tuberculosis*complex from a clinical specimen.
A person might have more than one discrete (separate and distinct) episode of TB. If dis­ease recurs ***within***any 12-month consecutive period after the patient completed therapy, count only one episode as a case. However, if TB disease recurs in a person, ***and***if >12 months have elapsed since the person completed TB therapy or the person was lost to supervision, the TB case is considered a separate episode and should be counted as a new case.
Mycobacterial diseases other than those caused by *M. tuberculosis*complex should not be counted in TB morbidity statistics unless concurrent TB occurs.
***A.* *Verified TB Cases***
**COUNT**
Count only verified TB cases that meet the laboratory or clinical case definitions (see Section II). TB diagnosis must be verified by the TB control officer or designee. The CDC surveillance case definition for TB (Appendix A) describes and defines the crite­ria to be used in the case definition for TB disease.
**DO NOT COUNT**
If diagnostic procedures have not been completed, do not count; wait for confirma­tion of disease. Do not count as a case of illness in a patient for whom two or more anti-TB medications have been prescribed for preventive therapy for exposure to multidrug-resistant TB or while the diagnosis is still pending.
***B.* *Nontuberculous Mycobacterial Disease***
**COUNT**
An episode of TB disease diagnosed concurrently with another nontuberculous my­cobacterial disease (NTM) should be counted as a TB case.
**DO NOT COUNT**
Disease attributed to or caused by NTM alone should not be counted as a TB case.
***C.* *TB Cases Reported at Death***
**COUNT**
TB cases first reported to the health department at the time of a person’s death are counted as incident cases, provided the person had current disease at the time of death. The TB control officer should verify the TB diagnosis.
**DO NOT COUNT**
Do not count as a case of TB if no evidence exists of current disease at the time of death or at autopsy.
***D. Immigrants, Refugees, Permanent Resident Aliens, Border Crossers,† and For­eign Visitors2***
**COUNT**
Immigrants and refugees who are examined after arriving in the United States and who receive a diagnosis of clinically active TB requiring anti-TB medications should be reported and counted by the locality of their residence at the time of diagnosis, regardless of citizenship status.
Border crossers who receive a TB diagnosis and who plan to receive anti-TB therapy from a locality in the United States for ≥90 days should be reported and counted by the locality where they receive anti-TB therapy.
Foreign visitors (e.g., students, commercial representatives, and diplomatic person­nel) who receive a diagnosis of TB, are receiving anti-TB therapy, ***and***have been or plan to remain in the United States for ≥90 days should be reported and counted by the locality of current residence.
**DO NOT COUNT**
Any person who received a TB diagnosis and who started anti-TB drugs in another country should not be counted as a new case but should be reported as a person with a verified noncountable TB case.
Border crossers and foreign visitors who receive a TB diagnosis and who receive anti-TB therapy from a locality in the United States for ≤89 days but who plan to return to their native country to continue therapy should not be reported or counted by the locality where they receive anti-TB therapy.
**†** Border crosser is by U.S. Citizenship and Immigration Services (USCIS)3 as “an alien resident of the United States reentering the country after an absence of less than six months in Canada or Mexico, or a nonresident alien entering the United States across the Canadian border for stays of no more than six months, or across the Mexican border for stays of no more than 72 hours.” Border crossers might go back and forth across the border frequently in a short period.
***E.* *Out-of-State or Out-of-Area Residents***
**COUNT**
A person’s TB case should be counted by the locality in which he or she resides at the time of diagnosis. TB in a person who has no address should be counted by the locality where TB is diagnosed and treated. The TB control officer should notify the out-of-state or out-of-area TB control officer of the person’s home locality to (1) de­termine whether the case has been counted already to avoid double counting, and (2) agree on which TB control office should count the case if it has not yet been counted.
**DO NOT COUNT**
Do not count a case in a patient with newly diagnosed TB who is an out-of-area resi­dent and whose TB has already been counted by the out-of-area TB control office.
***F.* *Migrants and Other Transients***
**COUNT**
Persons without any fixed U.S. residence are considered to be the public health re­sponsibility of their present locality, and their TB case should be reported and counted where diagnosed.
**DO NOT COUNT**
Cases among transient TB patients should not be counted when evidence exists that they have already been counted by another locality.
***G.* *Cases Occurring in Federal Facilities (e.g., Military and Veterans Administration Facilities)***
**COUNT**
Cases among military personnel, their dependents, or veterans should be reported and counted by the locality where the persons are residing in the United States at the time of diagnosis and initiation of treatment.
However, if military personnel or dependents are discovered to have TB at a military base outside the United States but are referred elsewhere for treatment (e.g., a military base located within the United States), the TB case should be reported and counted where treated and not where the diagnosis was made.
**DO NOT COUNT**
Do not count if the case was already counted by another locality in the United States.
***H.* *Cases Associated with the Indian Health Service***
**COUNT**
TB should be reported to the local health authority (e.g., state or county) and counted where diagnosed and treatment is initiated. However, for specific groups (e.g., the Na­vajo Nation) located in multiple states, health departments should discuss each case and determine which locality should count the case.
**DO NOT COUNT**
Do not count if the case was already counted by another locality.
***I.* *Cases Occurring in Correctional Facilities (e.g., Local, State, Federal, and Military)***
**COUNT**
Frequently, persons who reside in local, state, federal, or military correctional facili­ties are transferred or relocated within or between different correctional facilities. TB among these persons should be reported to the local health authority and counted by the locality where the diagnosis was made and treatment plans were initiated.
**DO NOT COUNT**
Do not count correctional facility residents’ TB cases that were counted elsewhere by another locality or correctional facility, even if treatment continues at another locale or correctional facility.
***J.* *Peace Corps, Missionaries, and Other Citizens Residing Outside the United States***
**DO NOT COUNT**
TB among persons who received their diagnosis outside the United States should not be counted. TB among these persons should be counted by the country in which they are residing, regardless of their plans to return to the United States for further evalua­tion or treatment.
IV. **Recommended Administrative Practices**
To promote uniformity in TB case counting, the following administrative procedures are recommended:
All TB cases verified by the 52 reporting areas with count authority (50 states, DC, and New York City) during the calendar year (by December 31) will be included in the an­nual U.S. incidence count for that year. All TB cases verified during the calendar year by a reporting area with count authority from one of the remaining eight reporting areas (Ameri­can Samoa, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, Puerto Rico, Republic of Palau, and U.S. Virgin Islands) are also counted but are not included in the annual incidence for the United States. Cases for which bacteriologic re­sults are pending or for which confirmation of disease is questionable for any other reason should not be counted until their status is clearly determined; they should be counted at the time they meet the criteria for counting. This means that a case reported in 1 calendar year might be included in the morbidity count for the following year. All reporting areas should ensure that agreement exists between final local and state TB figures reported to CDC. Re­porting areas might not use this recommended protocol. They may wait until the beginning of the following year when they have received and processed all of the TB cases for inclu­sion in the annual case count for the previous year. If reporting areas decide to revise their protocols, they should be aware that their TB trends might change.
Occasionally, TB is reported to health departments by telephone, by letter or fax, or on forms other than the RVCT. Such information should be accepted as an official morbid­ity report if sufficient details are provided; otherwise, the notification should be used as an indicator of a possible TB case (suspect) that should be investigated promptly for confirma­tion.V. **TB Surveillance Definitions**
**Case:**An episode of TB disease in a person meeting the laboratory or clinical criteria for TB as defined in “Tuberculosis Case Definition for Public Health Surveillance” (see Sec­tion II for criteria).
**Suspect:**A case for which a high index of suspicion exists for active TB (e.g., in a known contact of a person with active TB or in a person with signs or symptoms consistent with TB) and that is currently under evaluation.
**Verification of a TB case:**The process whereby a TB case, after the diagnostic evalua­tion is complete, is reviewed at the local level (e.g., state or county) by a TB control of­ficial who is familiar with TB surveillance definitions; if all the criteria for a TB case are met, the TB case is then verified and eligible for counting.
**Counting of a TB case:**The process whereby a reporting area with count author­ity evaluates verified TB cases against count criteria (e.g., assesses for case dupli­cation). These cases are then counted for morbidity in that locality (e.g., state or county) and reported to CDC for national morbidity counting. Noncountable, veri­fied cases should also be sent to CDC.
***M. Tuberculosis*Complex:**Because the majority of laboratories use tests that do not rou­tinely distinguish *M. tuberculosis*from closely related species, those laboratories report culture results as being positive or negative for *M. tuberculosis*complex. Although in approximately all cases of human disease, isolates in the *M. tuberculosis*complex are, in fact, *M. tuberculosis*, other species are possible. For example, one study in San Diego re­ported that 6% of human TB was caused by *M. bovis*; cultures from these cases would be reported by the majority of laboratories as being positive for *M. tuberculosis*complex.4 Other species in the *M. tuberculosis*complex include *M. africanum*, *M. micro­ti*, *M. canetii*, *M. caprae*, and *M. pinnipedii*. Although *M. microti*, *M. canettii*, *M. caprae*, and *M. pinnipedii*are newly described species, their inclusion in *M. tuberculosis*complex should not affect public health laboratories or programs because only a few laboratories identify to the species level. These seven species are almost identical in DNA homology studies. In terms of their ability to cause clinical disease or be transmissible from person to person, *M. bovis*, *M. africanum*, *M. microti*, *M. canettii*, *M. caprae*, and *M. pinnipe­dii*behave similar to *M. tuberculosis*; therefore, disease caused by any of the organisms should be reported as TB by using the RVCT form. The only exception is the BCG strain of *M. bovis*, which might be isolated from persons who have received the vaccine for protection against TB or as cancer immunotherapy; disease caused by the BCG strain of *M. bovis*should not be reported as TB.
**Nontuberculous mycobacteria:**Mycobacteria other than *M. tuberculosis*complex that can cause human infection or disease. Common nontuberculous mycobacteria (NTM) include *M. avium*complex (also known as “MAC”) (*M. avium*, *M. intracellulare*), *M. kansasii*, *M. marinum*, *M. scrofulaceum*, *M. chelonae*, *M. fortuitum*, and *M. simiae*. Other terms have been used to represent NTM, including “MOTT” (mycobacteria other than TB) and “atypical” mycobacteria.
**Reporting area:**Areas responsible for counting and reporting verified TB cases to CDC. A total of 60 areas report cases to CDC: the 50 states, DC, New York City, American Sa­moa, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, Puerto Rico, Republic of Palau, and U.S. Virgin Islands. The annual incidence of tubercu­losis for the United States is based on 52 of these reporting areas (the 50 states, DC, and New York City).
**Alien:**Defined by the U.S. Citizenship and Immigration Services (USCIS)3 as “any person not a citizen or national of the United States.” The term *alien*is further defined as follows:
**Border crosser:**Defined by  USCIS3 as “an alien resident of the United States reen­tering the country after an absence of less than six months in Canada or Mexico, or a nonresident alien entering the United States across the Canadian border for stays of no more than six months, or across the Mexican border for stays of no more than 72 hours.” Border crossers may go back and forth across the border frequently in a short period.**Class A TB with waiver2:**All applicants who have tuberculosis disease and have been granted a waiver.
**Class B1 TB, Pulmonary2**
**No Treatment**
Applicants who have medical history, physical exam, HIV, or chest radiographic findings indicative of pulmonary TB but have negative AFB sputum smears and cultures and have not received a diagnosis of TB or who can wait to have TB treatment started after immigration.
**Completed Treatment**
Applicants who received a diagnosis of pulmonary TB and successfully com­pleted directly observed therapy before immigration. The report cover sheet should indicate if the initial sputum smears and cultures were positive and if drug susceptibility testing results are available.
**Class B1 TB, Extrapulmonary2:**Applicants with evidence of extrapulmonary TB. Document the anatomic site of infection.
**Class B2 TB, Latent TB Infection (LTBI) Evaluation2:**Applicants who have a tuberculin skin test (TST) of ≥10-mm induration but oth­erwise have a negative evaluation for TB. The size of the TST reaction, the appli­cant’s status with respect to latent TB infection treatment, and the medications used should be documented. For applicants who have had >1 TST, if the applicant’s TST reaction converted, that should be documented (i.e., initial TST was ≤9-mm indura­tion but subsequent TST was ≥10-mm induration).
**Class B3 TB, Contact Evaluation2:**Applicants who are a recent contact of a known TB patient. The size of the appli­cant’s TST reaction should be documented. Information about the source patient, including name, alien number, relationship to contact, and type of TB should also be documented.
**Immigrant:**Defined by the USCIS3 as “an alien admitted to the United States as a lawful permanent resident. Immigrants are those persons lawfully accorded the privilege of residing permanently in the United States. They may be issued immigrant visas by the [U.S.] Department of State overseas or adjusted to per­manent resident status by the USCIS of the United States.”
**Permanent Resident Alien:**See *Immigrant*.Counting of a TB case
**Waivers2:**A provision allows applicants undergoing pulmonary or laryngeal TB treatment to petition for a Class A TB with waiver. Waivers should be pursued for any immigrant or refugee who has a complicated clinical course and would ben­efit from receiving TB treatment in the United States. Applicants with diagnosed TB disease who are both smear- and culture-negative and will be traveling to the United States before start of treatment do not need to complete the waiver process.VI. ReferencesCDC. Recommendations for counting reported tuberculosis cases. In: Reported Tuberculo­sis in the United States, 1996. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 1997:61–8.
CDC. 2007 Technical Instructions for Tuberculosis Screening and Treatment for Pan­el Physicians. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2013. Available at: http://www.cdc.gov/immigrantrefugeehealth/exams/ti/panel/tuberculosis-panel-technical-instructions.html
US Department of Homeland Security (DHS). U.S. Citizenship and Immigration Services [Homepage]. Washington, DC: DHS; 2016. Available at: http://uscis.govexternal icon
TC Rodwell, M Moore, KS Moser, SK Brodine, SA Strathdee. Tuberculosis from Myco­bacterium bovis in Binational Communities, United States.*Emerg Infect Dis* 2008 Jun; 14(6): 909–916.
							
					
						Page last reviewed:  October 22, 2018					Content source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue